Eli Lilly & Co (LLY) Stock Forecast & Price Target

Compare

178 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

LLY Analyst Ratings

Strong Buy

18 Buy

4 Hold

0 Sell

Based on 22 analysts giving stock ratings to

Eli

Lilly & Co

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

LLY Stock 12 Month Forecast

Average Price Target

€791.09

▲(6.50% Upside)

Based on 22 Wall Street analysts offering 12 month price targets for Eli Lilly & Co in the last 3 months. The average price target is €791.09 with a high forecast of €948.31 and a low forecast of €603.47. The average price target represents a 6.50% change from the last price of €742.80.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"602":"€602","949":"€949","688.75":"€688.8","775.5":"€775.5","862.25":"€862.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":948.31429,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€948.31</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":791.092401757,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€791.09</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":603.47273,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€603.47</span>\n  </div></div>","useHTML":true}}],"tickPositions":[602,688.75,775.5,862.25,949],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2025","6":"Apr<br/>2025","9":"Jul<br/>2025","12":"Oct<br/>2025","25":"Oct<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,691.6,711.3472530769232,731.0945061538462,750.8417592307693,770.5890123076923,790.3362653846154,810.0835184615385,829.8307715384616,849.5780246153846,869.3252776923077,889.0725307692308,908.8197838461539,928.567036923077,{"y":948.31429,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,691.6,699.2532616736154,706.9065233472307,714.5597850208461,722.2130466944616,729.866308368077,737.5195700416923,745.1728317153077,752.826093388923,760.4793550625384,768.1326167361538,775.7858784097692,783.4391400833846,{"y":791.092401757,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,691.6,684.8209792307692,678.0419584615385,671.2629376923077,664.4839169230769,657.7048961538461,650.9258753846154,644.1468546153847,637.3678338461539,630.5888130769231,623.8097923076923,617.0307715384615,610.2517507692307,{"y":603.47273,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":794.213,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 73,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":755.311,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 58,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":757.042,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 60,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":739.15,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 59,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":785.173,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 68,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":861.984,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 65,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":753.85,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 63,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":785.315,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 64,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":648.559,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 75,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":666.619,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 76,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":653.747,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 80,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":618.3,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 74,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":691.6,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 77,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target€948.31

Average Price Target€791.09

Lowest Price Target€603.47

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Tim Anderson

Bank of America Securities

€773.27→€816.23

Buy

9.89%

Upside

Reiterated

10/31/25

Analysts Conflicted on These Healthcare Names: Eli Lilly & Co (NYSE: LLY), Celldex (NASDAQ: CLDX) and Illumina (NASDAQ: ILMN)We rate LLY as Buy, reflecting its outsized/durable growth potential versus peers, and the very full catalyst path in front of it, at a valuation we think is still reasonable given this profile. Admittedly, there are lots of moving parts to the LLY story, and it’s not for the faint at heart given binary event risk, both near- and intermediate-term. To us, LLY undisputably remains in pole position in obesity. For more information, see these recent reports: Pipeline Preview. For a prior, in-depth discussion of LLY’s obesity portfolio, see note Highlights from “Pipelines of R&D.

Srikripa Devarakonda

Truist Financial

€891.84

Buy

20.06%

Upside

Reiterated

10/31/25

Truist Financial Sticks to Their Buy Rating for Eli Lilly & Co (LLY)

Akash Tewari

Jefferies

€777.57→€838.57

Buy

12.89%

Upside

Reiterated

10/31/25

Eli Lilly & Co (LLY) Gets a Buy from Jefferies

Geoff Meacham

Citi

―

Buy

―

Reiterated

10/31/25

Citi Reaffirms Their Buy Rating on Eli Lilly & Co (LLY)

Terence Flynn

Morgan Stanley

€878.95→€918.47

Buy

23.65%

Upside

Reiterated

10/31/25

Morgan Stanley Keeps Their Buy Rating on Eli Lilly & Co (LLY)

Veda Pharmyne

TR | OpenAI - 4o

€780.14→€819.67

Buy

10.35%

Upside

Reiterated

10/31/25

AI Generated ArticleAI Generated Article

Carter Gould

Cantor Fitzgerald

€794.75→€846.3

Buy

13.93%

Upside

Reiterated

10/31/25

Eli Lilly price target raised to $985 from $925 at Cantor FitzgeraldEli Lilly price target raised to $985 from $925 at Cantor Fitzgerald

Steve Scala

TD Cowen

€824.82

Buy

11.04%

Upside

Reiterated

10/30/25

Eli Lilly & Co (LLY) Gets a Buy from TD Cowen

Evan Seigerman

BMO Capital

€721.72→€799.05

Buy

7.57%

Upside

Reiterated

10/30/25

BMO Capital Keeps Their Buy Rating on Eli Lilly & Co (LLY)

Courtney Breen

Bernstein

€945.11

Buy

27.24%

Upside

Reiterated

10/27/25

Bernstein Reaffirms Their Buy Rating on Eli Lilly & Co (LLY)

David Risinger

Leerink Partners

€614.32

Hold

-17.30%

Downside

Reiterated

10/23/25

Leerink Partners Keeps Their Hold Rating on Eli Lilly & Co (LLY)

Asad Haider

Goldman Sachs

€752.65→€755.23

Buy

1.67%

Upside

Reiterated

10/20/25

Eli Lilly & Co: Strategic Positioning and Clinical Advancements Drive Buy Rating

Chris Schott

J.P. Morgan

―

Buy

―

Reiterated

10/17/25

J.P. Morgan Sticks to Its Buy Rating for Eli Lilly & Co (LLY)

Seamus Fernandez

Guggenheim

€814.51

Buy

9.65%

Upside

Reiterated

10/15/25

Guggenheim Remains a Buy on Eli Lilly & Co (LLY)

Hans Engel

Erste Group

―

Buy

―

Upgraded

10/13/25

Eli Lilly upgraded to Buy from Hold at Erste GroupEli Lilly upgraded to Buy from Hold at Erste Group

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Tim Anderson

Bank of America Securities

€773.27→€816.23

Buy

9.89%

Upside

Reiterated

10/31/25

Srikripa Devarakonda

Truist Financial

€891.84

Buy

20.06%

Upside

Reiterated

10/31/25

Truist Financial Sticks to Their Buy Rating for Eli Lilly & Co (LLY)

Akash Tewari

Jefferies

€777.57→€838.57

Buy

12.89%

Upside

Reiterated

10/31/25

Eli Lilly & Co (LLY) Gets a Buy from Jefferies

Geoff Meacham

Citi

―

Buy

―

Reiterated

10/31/25

Citi Reaffirms Their Buy Rating on Eli Lilly & Co (LLY)

Terence Flynn

Morgan Stanley

€878.95→€918.47

Buy

23.65%

Upside

Reiterated

10/31/25

Morgan Stanley Keeps Their Buy Rating on Eli Lilly & Co (LLY)

Veda Pharmyne

TR | OpenAI - 4o

€780.14→€819.67

Buy

10.35%

Upside

Reiterated

10/31/25

AI Generated ArticleAI Generated Article

Carter Gould

Cantor Fitzgerald

€794.75→€846.3

Buy

13.93%

Upside

Reiterated

10/31/25

Eli Lilly price target raised to $985 from $925 at Cantor FitzgeraldEli Lilly price target raised to $985 from $925 at Cantor Fitzgerald

Steve Scala

TD Cowen

€824.82

Buy

11.04%

Upside

Reiterated

10/30/25

Eli Lilly & Co (LLY) Gets a Buy from TD Cowen

Evan Seigerman

BMO Capital

€721.72→€799.05

Buy

7.57%

Upside

Reiterated

10/30/25

BMO Capital Keeps Their Buy Rating on Eli Lilly & Co (LLY)

Courtney Breen

Bernstein

€945.11

Buy

27.24%

Upside

Reiterated

10/27/25

Bernstein Reaffirms Their Buy Rating on Eli Lilly & Co (LLY)

David Risinger

Leerink Partners

€614.32

Hold

-17.30%

Downside

Reiterated

10/23/25

Leerink Partners Keeps Their Hold Rating on Eli Lilly & Co (LLY)

Asad Haider

Goldman Sachs

€752.65→€755.23

Buy

1.67%

Upside

Reiterated

10/20/25

Eli Lilly & Co: Strategic Positioning and Clinical Advancements Drive Buy Rating

Chris Schott

J.P. Morgan

―

Buy

―

Reiterated

10/17/25

J.P. Morgan Sticks to Its Buy Rating for Eli Lilly & Co (LLY)

Seamus Fernandez

Guggenheim

€814.51

Buy

9.65%

Upside

Reiterated

10/15/25

Guggenheim Remains a Buy on Eli Lilly & Co (LLY)

Hans Engel

Erste Group

―

Buy

―

Upgraded

10/13/25

Eli Lilly upgraded to Buy from Hold at Erste GroupEli Lilly upgraded to Buy from Hold at Erste Group

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Eli Lilly & Co

1 Month

xxx

Success Rate

31/42 ratings generated profit

Average Return

+4.48%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 73.81% of your transactions generating a profit, with an average return of +4.48% per trade.

3 Months

xxx

Success Rate

31/42 ratings generated profit

Average Return

+9.60%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 73.81% of your transactions generating a profit, with an average return of +9.60% per trade.

1 Year

Geoff MeachamCiti

Success Rate

39/42 ratings generated profit

Average Return

+35.64%

reiterated a buy rating 4 days ago

Copying Geoff Meacham's trades and holding each position for 1 Year would result in 92.86% of your transactions generating a profit, with an average return of +35.64% per trade.

2 Years

xxx

Success Rate

32/35 ratings generated profit

Average Return

+27.64%

reiterated a xxx

rating 20 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 91.43% of your transactions generating a profit, with an average return of +27.64% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

LLY Analyst Recommendation Trends

Rating

Jun 25

Jul 25

Aug 25

Sep 25

Oct 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, LLY has received 77 Buy Ratings, 14 Hold Ratings, and 0 Sell Ratings. LLY average Analyst price target in the past 3 months is 791.09.

Each month's total comprises the sum of three months' worth of ratings.

LLY Financial Forecast

LLY Earnings Forecast

Next quarter’s earnings estimate for LLY is €6.07 with a range of €5.53 to €7.59. The previous quarter’s EPS was €6.07. LLY beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.09% of the time in the same period. In the last calendar year LLY has Preformed in-line its overall industry.

LLY Sales Forecast

Next quarter’s sales forecast for LLY is €15.13B with a range of €14.66B to €15.47B. The previous quarter’s sales results were €15.22B. LLY beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.55% of the time in the same period. In the last calendar year LLY has Preformed in-line its overall industry.

LLY Stock Forecast FAQ

What is DE:LLY’s average 12-month price target, according to analysts?

Based on analyst ratings, Eli Lilly And Company’s 12-month average price target is 791.09.

What is DE:LLY’s upside potential, based on the analysts’ average price target?

Eli Lilly And Company has 6.50% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Eli Lilly And Company a Buy, Sell or Hold?

Eli Lilly And Company has a consensus rating of Strong Buy, which is based on 18 buy ratings, 4 hold ratings and 0 sell ratings.

What is Eli Lilly And Company’s share price target?

The average share price target for Eli Lilly And Company is 791.09. This is based on 22 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is €948.31 ,and the lowest forecast is €603.47. The average share price target represents 6.50% Increase from the current price of €742.8.

What do analysts say about Eli Lilly And Company?

Eli Lilly And Company’s analyst rating consensus is a Strong Buy. This is based on the ratings of 22 Wall Streets Analysts.

How can I buy shares of Eli Lilly And Company?

To buy shares of DE:LLY, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Eli Lilly & Co (LLY) Stock Forecast & Price Target

LLY Analyst Ratings

LLY Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Eli Lilly & Co

LLY Analyst Recommendation Trends

LLY Financial Forecast

LLY Earnings Forecast

LLY Sales Forecast

LLY Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts